US FDA review of lisocabtagene maraleucel (liso-cel) for the treatment of relapsed or refractory large B-cell lymphoma delayed

The US FDA has been unable to conduct an inspection of a third-party manufacturing facility in Texas during the current review cycle due to travel restrictions related to the COVID-19 pandemic, and will be deferring action on the application until this can be completed.

Source:

Biospace Inc.